48
Participants
Start Date
September 30, 2021
Primary Completion Date
December 31, 2022
Study Completion Date
July 31, 2023
Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib
TQB2450 injection: 1200 mg, i.v.gtt , d1;Anlotinib 10mg, po.qd , d1-14;Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to Anlotinib (10mg, po.qd , d1-14)+TQB2450 injection(1200 mg, i.v.gtt , d1). The regimen is repeated every 3 weeks until the disease progresses.
Paclitaxel + Cisplatin + TQB2450 injection
TQB2450 injection: 1200 mg, i.v.gtt , d1;Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to TQB2450 injection(1200 mg, i.v.gtt , d1). The regimen is repeated every 3 weeks until the disease progresses.
Henan Provincial People's Hospital, Zhengzhou
Henan Cancer Hospital, Zhengzhou
AnYang Tumor Hospital, Anyang
The People's Hospital Of AnYang City, Anyang
First Affiliated Hospital of Henan University of Science and Technolog, Luoyang
Collaborators (1)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY
Henan Cancer Hospital
OTHER_GOV